Sage Journals: Discover world-class research

Abstract

Objectives

Regulatory T cells (Tregs) mediate immunomodulation and protect against atherosclerosis. It is considered that reducing the amount of pro-inflammatory mediators could be achieved by enhancing the anti-inflammatory response, and this may be considered one of the main targets for therapy development. The inhibitory cytokines secreted by Tregs mainly include interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β). Based on its known immunosuppressive involvement with other inflammatory disorders, we hypothesized that the newly characterized cytokine interleukin-37 (IL-37) might be associated with the inhibitory functions of Treg in atherosclerosis. Immune regulatory functions of IL-37 have not been completely clarified. Accordingly, we speculated that IL-37 might play a regulatory role in the immunosuppression of Tregs in atherosclerotic disease.

Methods

Real-time polymerase chain reaction and enzyme linked immunosorbent assay were used to test gene expression and protein levels of IL-37 in peripheral blood and localized freshly resected arterial tissues from 84 patients with peripheral arterial occlusive disease and 50 non-atherosclerotic subjects. Results were correlated to disease hallmarks. We also evaluated the ability of recombinant IL-37 to modulate Treg cytokine secretion and T cell inhibition in relation to atherosclerotic disorder in vitro.

Results: Our results revealed that IL-37 was increased in patients with chronic lower limb atherosclerotic ischemia, compared to non-atherosclerotic controls. In addition, the expression levels of circulating IL-37 correlated with disease severity of chronic lower limb ischemia. Supplementation with rIL-37 augmented levels of released IL-10 and TGF-β in supernatants of T cells co-cultured with Tregs in the enrolled patients.

Conclusions: Results suggest a role for IL-37 in mediating anti-inflammatory functions in the atherosclerotic process, potentially involving enhancement of Treg inhibitory function and anti-inflammatory cytokine secretion with a particularly marked direct response in severe disease.

Keywords

Interleukin-37 Treg cells peripheral atherosclerosis interleukin-10 transforming growth factor-beta

Get full access to this article

View all access options for this article.

References

Wong

Meredith

Lin

, et al. The biological role of inflammation in atherosclerosis. Can J Cardiol 2012; 28: 631–641.

Kullo

Rooke

WT.

Clinical practice. Peripheral artery disease. N Engl J Med 2016; 374: 861–871.

Shu

Santulli

Update on peripheral artery disease: Epidemiology and evidence-based facts. Atherosclerosis 2018; 275: 379–381.

Norgren

Hiatt

Dormandy

, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 33: S5–S67.

Ross

Atherosclerosis—An inflammatory disease. N Engl J Med 1999; 340: 115–126.

Komatsu

Takayanagi

Regulatory T cells in arthritis. Prog Mol Biol Transl Sci 2015; 136: 207–215.

Amin

Sasaki

Hirata

KI.

Regulatory T cell immunity in atherosclerosis. Acta Med Indones 2017; 49: 63–68.

Arce-Sillas

Alvarez-Luquin

Tamaya-Dominguez

, et al. Regulatory T cells: Molecular actions on effector cells in immune regulation. J Immunol Res 2016; 2016: 1720827.

Kumar

McDonnell

Lehr

, et al. Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem 2000; 275: 10308–10314.

10.

Boraschi

Lucchesi

Hainzlet

IL-37: A new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 2011; 22: 127–147.

11.

Nold

Nold-Petry

Zepp

, et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010; 11: 1014–1022.

12.

Ding

Zhu

Xiao

, et al. The role of IL-37 in cancer. Med Oncol 2016; 33: 68.

13.

Zhao

Liu

Insights into IL-37, the role in autoimmune diseases. Autoimmun Rev 2015; 14: 1170–1175.

14.

Tete

Tripodi

Rosati

, et al. IL-37 (IL-1F7) the newest anti-inflammatory cytokine which suppresses immune responses and inflammation. Int J Immunopathol Pharmacol 2012; 25: 31–38.

15.

Moretti

Bozza

Oikonomou

, et al. IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS Pathog 2014; 10: e1004462.

16.

McCurdy

Liu

Yap

, et al. Potential role of IL-37 in atherosclerosis. Cytokine 2019; 122: 154–169.

17.

Shaoyuan

Ming

Yulang

, et al. Increased IL-37 in atherosclerotic disease could be suppressed by atorvastatin therapy. Scand J Immunol 2015; 82: 328–336.

18.

Hoeke

Padmini

Van Diepen

, et al. The effects of selective hematopoietic expression of human IL-37 on systemic inflammation and atherosclerosis in LDLr-deficient mice. Int J Mol Sci 2017; 18: 1672.

19.

Zeng

Huang

, et al. Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediators Inflamm 2014; 2014: 165742.

20.

Huang

Hou

Zhang

, et al. Protective effect of the polarity of macrophages regulated by IL-37 on atherosclerosis. Genet Mol Res 2016; 15.

21.

Yin

Naji

Xia

, et al. Genomic variant in IL-37 confers a significant risk of coronary artery disease. Sci Rep 2017; 7: 42175.

22.

Welch

Andras

Chappell

, et al. Ankle brachial index for the diagnosis of lower limb peripheral arterial disease. Cochrane Database Syst Rev 2016; 9: CD010680.

23.

Rutherford

Baker

Ernst

, et al. Recommended standards for reports dealing with lower extremity ischemia: Revised version. J Vasc Surg 1997; 26: 517–538.

24.

Fuss

Kanof

Smith

, et al. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol 2009; Chapter 7.

25.

Wang

Jiang

, et al. Effects of interleukin-37 on cardiac function after myocardial infarction in mice. Int J Clin Exp Pathol 2015; 8: 5247–5251.

26.

Wen

, et al. IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: Its correlation with disease activity. J Transl Med 2014; 16: 12–69.

27.

Wang

, et al. Increased expression of IL-37 in patients with Graves’ disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells. PLoS One 2014; 9: e107183.

28.

Yang

Fang

Chen

, et al. Elevated plasma interleukin-37 playing an important role in acute coronary syndrome through suppression of ROCK activation. Oncotarget 2017; 8: 9686–9695.

29.

, et al. Interleukin-37 elevation in patients with atrial fibrillation. Clin Cardiol 2017; 40: 66–72.

30.

Zeng

Meng

, et al. The potential role of IL-37 in atherosclerosis. Pharmazie 2013; 68: 857–860.

31.

Luo

Cai

Liu

, et al. Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci USA 2014; 111: 15178–15183.

32.

Meng

, et al. Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice. Clin Exp Immunol 2014; 176: 438–451.

33.

McNamee

Masterson

Jedlicka

, et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci USA 2011; 108: 16711–16716.

34.

Libby

Lichtman

Hansson

GK.

Immune effector mechanisms implicated in atherosclerosis: From mice to humans. Immunity 2013; 38: 1092–1104.

35.

Bäck

Hansson

GK.

Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol 2015; 12: 199–211.

36.

Ait-Oufella

Taleb

Mallat

, et al. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31: 969–979.

37.

Yang

Zhang

Lian

, et al. IL-37 inhibits IL-18-induced tubular epithelial cell expression of pro-inflammatory cytokines and renal ischemia-reperfusion injury. Kidney Int 2015; 87: 396–408.

38.

Sojka

Hughson

Fowell

DJ.

CTLA-4 is required by CD4+CD25+Treg to control CD4+ T-cell lymphopenia-induced proliferation. Eur J Immunol 2009; 39: 1544–1551.

39.

Zhu

Sun

, et al. Interleukin-37 and dendritic cells treated with interleukin-37 plus troponin I ameliorate cardiac remodeling after myocardial infarction. J Am Heart Assoc 2016; 5: e004406.

40.

Michael

Salter

Ramji

DP.

TGF-beta inhibits the uptake of modified low density lipoprotein by human macrophages through a Smad-dependent pathway: A dominant role for Smad-2. Biochim Biophys Acta 2012; 1822: 1608–1616.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.13 MB

The novel role of IL-37 to enhance the anti-inflammatory response of regulatory T cells in patients with peripheral atherosclerosis